EVO
Price
$1.32Alerts
Change
-$0.13 (-8.97%)
Updated
Nov 20 closing price
Capitalization
578.21M
Intraday BUY SELL Signals
RGC
Price
$4.18Alerts
Change
-$0.18 (-4.13%)
Updated
Nov 20 closing price
Capitalization
2.61B
46 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

EVO vs RGC

EVO vs RGC Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
EVO vs. RGC commentary
Nov 22, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EVO is a Hold and RGC is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for EVO with price predictions
Nov 20, 2026

Momentum Indicator for EVO turns negative, indicating new downward trend

EVO saw its Momentum Indicator move below the 0 level on November 17, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 100 similar instances where the indicator turned negative. In 88 of the 100 cases, the stock moved further down in the following days. The odds of a decline are at 88%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for EVO turned negative on November 17, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In 34 of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at 81%.

EVO moved below its 50-day moving average on November 13, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where EVO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.

Bullish Trend Analysis

The RSI Indicator entered the oversold zone -- be on the watch for EVO's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

The 10-day moving average for EVO crossed bullishly above the 50-day moving average on November 10, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 17 of 20 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 85%.

Following a +14.52% 3-day Advance, the price is estimated to grow further. Considering data from situations where EVO advanced for three days, in 187 of 276 cases, the price rose further within the following month. The odds of a continued upward trend are 68%.

EVO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In 77 of 140 cases where EVO Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 55%.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 2 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 77 (best 1 - 100 worst), indicating slightly worse than average price growth. EVO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 91 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.746) is normal, around the industry mean (6.379). EVO's P/E Ratio (476.190) is considerably higher than the industry average of (0.548). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.061) among similar stocks. P/S Ratio (0.695) is also within normal values, averaging (183.387).

The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EVO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.

A.I.Advisor
a Summary for RGC with price predictions
Nov 20, 2026

RGC sees MACD Histogram crosses below signal line

RGC saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on October 26, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 36 instances where the indicator turned negative. In 34 of the 36 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 26, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on RGC as a result. In 80 of 90 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 89%.

RGC moved below its 50-day moving average on October 30, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for RGC crossed bearishly below the 50-day moving average on November 05, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 14 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 88%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where RGC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.

RGC broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for RGC entered a downward trend on November 20, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 18 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Fundamental Analysis (Ratings)

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron PE Growth Rating for this company is 52 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 55 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: RGC's P/B Ratio (317.076) is very high in comparison to the industry average of (6.379). RGC's P/E Ratio (-606.863) is considerably lower than the industry average of (0.548). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.061) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (183.387).

The Tickeron Price Growth Rating for this company is 92 (best 1 - 100 worst), indicating slightly worse than average price growth. RGC’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RGC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.

FUNDAMENTALS RATINGS
EVO vs RGC: Fundamental Ratings
EVO
RGC
OUTLOOK RATING
1..100
7751
VALUATION
overvalued / fair valued / undervalued
1..100
91
Overvalued
55
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
96100
PRICE GROWTH RATING
1..100
7792
P/E GROWTH RATING
1..100
252
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

RGC's Valuation (55) in the Movies Or Entertainment industry is somewhat better than the same rating for EVO (91) in the null industry. This means that RGC’s stock grew somewhat faster than EVO’s over the last 12 months.

RGC's Profit vs Risk Rating (100) in the Movies Or Entertainment industry is in the same range as EVO (100) in the null industry. This means that RGC’s stock grew similarly to EVO’s over the last 12 months.

EVO's SMR Rating (96) in the null industry is in the same range as RGC (100) in the Movies Or Entertainment industry. This means that EVO’s stock grew similarly to RGC’s over the last 12 months.

EVO's Price Growth Rating (77) in the null industry is in the same range as RGC (92) in the Movies Or Entertainment industry. This means that EVO’s stock grew similarly to RGC’s over the last 12 months.

EVO's P/E Growth Rating (2) in the null industry is somewhat better than the same rating for RGC (52) in the Movies Or Entertainment industry. This means that EVO’s stock grew somewhat faster than RGC’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
EVORGC
RSI
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 2 days ago
86%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
67%
Bullish Trend 2 days ago
83%
Momentum
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
89%
MACD
ODDS (%)
Bearish Trend 2 days ago
81%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
79%
Bearish Trend 2 days ago
88%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
77%
Bearish Trend 2 days ago
89%
Advances
ODDS (%)
Bullish Trend 17 days ago
68%
N/A
Declines
ODDS (%)
Bearish Trend 2 days ago
80%
Bearish Trend 2 days ago
89%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
74%
Bearish Trend 6 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
55%
Bearish Trend 2 days ago
90%
COMPARISON
Comparison
Nov 22, 2026
Stock price -- (EVO: $1.32 vs. RGC: $4.18)
Brand notoriety: EVO and RGC are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: EVO: 78% vs. RGC: 48%
Market capitalization -- EVO: $578.21M vs. RGC: $2.61B
EVO [@Pharmaceuticals: Generic] is valued at $578.21M. RGC’s [@Pharmaceuticals: Generic] market capitalization is $2.61B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $2.12K to $68.49B. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $4.46B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

EVO’s FA Score shows that 1 FA rating(s) are green while RGC’s FA Score has 0 green FA rating(s).

  • EVO’s FA Score: 1 green, 4 red.
  • RGC’s FA Score: 0 green, 5 red.
According to our system of comparison, EVO is a better buy in the long-term than RGC.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

EVO’s TA Score shows that 6 TA indicator(s) are bullish while RGC’s TA Score has 2 bullish TA indicator(s).

  • EVO’s TA Score: 6 bullish, 4 bearish.
  • RGC’s TA Score: 2 bullish, 7 bearish.
According to our system of comparison, EVO is a better buy in the short-term than RGC.

Price Growth

EVO (@Pharmaceuticals: Generic) experienced а -16.46% price change this week, while RGC (@Pharmaceuticals: Generic) price change was -15.38% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -7.72%. For the same industry, the average monthly price growth was -10.88%, and the average quarterly price growth was -13.25%.

Reported Earning Dates

RGC is expected to report earnings on Jan 06, 2027.

Industries' Descriptions

@Pharmaceuticals: Generic (-7.72% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

View a ticker or compare two or three
Interact to see
Advertisement

RGC and

Correlation & Price change

A.I.dvisor tells us that RGC and HIMS have been poorly correlated (+22% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that RGC and HIMS's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RGC
1D Price
Change %
RGC100%
-4.13%
HIMS - RGC
22%
Poorly correlated
-8.86%
QNTM - RGC
21%
Poorly correlated
-9.15%
ACB - RGC
21%
Poorly correlated
-2.35%
KMDA - RGC
21%
Poorly correlated
-1.15%
EVO - RGC
16%
Poorly correlated
-8.97%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
IPI29.29-0.21
-0.71%
Intrepid Potash
EVR271.82-13.71
-4.80%
Evercore
NCI4.02-0.24
-5.63%
Neo-Concept International Group Holdings Ltd
UPST15.66-1.34
-7.88%
Upstart Holdings
ACRV1.15-0.25
-17.86%
Acrivon Therapeutics